menu search

INZY / Inozyme Pharma to Present at the Jefferies Healthcare Conference

Inozyme Pharma to Present at the Jefferies Healthcare Conference
BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Douglas A. Treco, Ph.D., the company's chief executive officer and chairman of the board, will present at the Jefferies Healthcare Conference on Friday, June 9, 2023, from 9:30-9:55 a.m. ET. Read More
Posted: Jun 2 2023, 07:30
Author Name: GlobeNewsWire
Views: 102642

INZY News  

Inozyme Pharma, Inc. (INZY) Moves to Buy: Rationale Behind the Upgrade

By Zacks Investment Research
October 10, 2023

Inozyme Pharma, Inc. (INZY) Moves to Buy: Rationale Behind the Upgrade

Inozyme Pharma, Inc. (INZY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might more_horizontal

3 Penny Stocks To Buy According To Insiders In August 2023

By PennyStocks
August 4, 2023

3 Penny Stocks To Buy According To Insiders In August 2023

Penny stocks are an interesting asset class when it comes to making money in the stock market. Their inherent risk/reward makeup lends to heavy specul more_horizontal

Inozyme Pharma to Present at the Jefferies Healthcare Conference

By GlobeNewsWire
June 2, 2023

Inozyme Pharma to Present at the Jefferies Healthcare Conference

BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing nove more_horizontal

Inozyme Pharma: Rare Disease Player Merits Revaluation Higher After POC Data

By Seeking Alpha
February 21, 2023

Inozyme Pharma: Rare Disease Player Merits Revaluation Higher After POC Data

Shares are down 58% over the past year. Enzyme replacement therapy is an attractive area of drug development with less risk than more exotic modalitie more_horizontal

Inozyme Pharma Post Encouraging Early Data From Genetic Disorder Trial

By Benzinga
July 20, 2022

Inozyme Pharma Post Encouraging Early Data From Genetic Disorder Trial

Inozyme Pharma Inc (NASDAQ: INZY) has announced preliminary biomarker, safety, and pharmacokinetic (PK) data from the first three subjects in the P more_horizontal

Inozyme Pharma Starts Dosing In INZ-701 Trial For Calcification Disorders

By Benzinga
April 12, 2022

Inozyme Pharma Starts Dosing In INZ-701 Trial For Calcification Disorders

Inozyme Pharma Inc (NASDAQ: INZY) has dosed the first patient in its Phase 1/2 trial of INZ-701 in adult patients with ABCC6 Deficiency. Also, the more_horizontal

Why Inozyme Pharma Shares Are Jumping Today

By Benzinga
April 4, 2022

Why Inozyme Pharma Shares Are Jumping Today

Inozyme Pharma Inc (NASDAQ: INZY) announced preliminary biomarker, safety, and pharmacokinetic (PK) data from the first three patients treated in t more_horizontal


Search within

Pages Search Results: